A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis

NCT07443306 | Recruiting Phase 2

• 1 other identifier: FMF-04
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 2

Brief Summary

This trial adopts a single arm, open label, multi center clinical trial design, with a planned enrollment of approximately 64 participants in the moderate to high risk MF trial who are refractory, relapsed, or intolerant to JAK inhibitor . Select successful trial participants and allocate flonoltinib maleate tablets based on platelet count levels during the screening period, qd,Oral administration on an empty stomach until the participants meet the withdrawal criteria.

Conditions

MF

Outcome Measures

Primary Outcomes (1)

• Percentage of subjects with >=35% reduction in spleen volume from baseline

  Week 24

Secondary Outcomes (3)

• Spleen response time

  Week 12,week 24

• MPN-SAF TSS Total Symptom Score and Baseline Comparison Decrease

  Week 2,week 4,week 8,week 12,week 24

• Overall survival period

  Week 2,week 4,week 8,week 12,week 24

Study Arms (1)

Flonoltinib maleate

EXPERIMENTAL

Allocate 50mg or 75mg flonoltinib maleate tablets once daily on an empty stomach based on platelet count levels during the screening period

Drug: Flonoltinib Maleate

Interventions

Flonoltinib Maleate DRUG

Allocate flonoltinib maleate tablets 50mg or 75mg once daily on an empty stomach based on platelet count levels during the screening period

Flonoltinib maleate

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age range of 18-80 years old (including threshold), gender not limited;
• Patients diagnosed with primary myelofibrosis (PMF) according to WHO criteria (2016 edition) or patients diagnosed with post polycythemia vera myelofibrosis (PPV-MF) or post thrombocytopenia myelofibrosis (PET-MF) according to IWG-MRT criteria;
• Patients with myelofibrosis assessed as intermediate-2 or high-risk according to the dynamic international prognostic scoring system (DIPSS) prognostic classification criteria;or patients with intermediate-1 myelofibrosis who exhibit hepatosplenomegaly and require treatment;
• MF patients who have received JAK inhibitor treatment in the past and meet the criteria of refractory/recurrent/intolerant;
• Expected survival period greater than 24 weeks;
• ECOG score 0-2 points;
• Splenomegaly: Palpation of the splenic margin reaching or exceeding 5cm below the rib (distance from the intersection of the left clavicle midline and left rib margin to the farthest point of the spleen); Or due to physical reasons (such as obesity), it may not be palpable, but MRI/CT spleen evaluation during screening confirms a volume of \>= 450 cm\^3;
• Peripheral blood and bone marrow blasts \<=10%;
• Within 7 days prior to randomization, ANC \>=1.0 × 10\^9/L, platelet count \>=100 × 10\^9/L, HGB\>60 g/L ;
• Within 7 days prior to randomization, the main organ functions were generally normal, meeting the following criteria: ALT and AST \<= 2.5 × ULN; TBIL\<=2.0×ULN; Serum creatinine \<=1.5 × ULN or serum creatinine clearance rate (Ccr)\>50 mL/min; INR, PT, and APTT \<= 1.5 × ULN;
• Can understand and voluntarily sign an informed consent form..

You may not qualify if:

• The toxic reactions of previous anti-cancer treatments have not recovered to grade 1 or below (excluding hair loss), or have not fully recovered from previous surgeries(such as undergoing major surgery within 4 weeks);
• Allergy to experimental drugs and their excipients;
• For any significant clinical and laboratory abnormalities, the researchers believe that they affect the safety evaluators, such as: a. uncontrollable diabetes - fasting blood glucose\>250 mg/dL (13.9 mmol/L), b. hypertension and cannot be reduced to the following range after treatment with two or more antihypertensive drugs (systolic blood pressure\<160 mmHg, diastolic blood pressure\<100 mmHg), c. peripheral neuropathy;
• Patients with a history of congestive heart failure (NYHA grade III or above), unstable angina or myocardial infarction, cerebrovascular accidents or thromboembolism within the first 6 months of screening;
• Individuals with impaired cardiac function (those with ejection fraction\<45% detected by echocardiography, congenital ventricular arrhythmia, QTcF\>450 ms on electrocardiogram (males), QTcF\>470 ms on electrocardiogram (females), or those with arrhythmia requiring treatment at the time of screening);
• Patients with congenital or acquired bleeding disorders or unstable thrombotic diseases requiring anticoagulant therapy;
• Any active infections requiring systemic treatment (oral, intravenous, subcutaneous, intramuscular, etc.) within 14 days prior to enrollment;
• Individuals who have experienced active tuberculosis infection within the 48 weeks prior to screening or those who have been diagnosed with latent tuberculosis infection during the screening period (those diagnosed with latent tuberculosis infection must complete preventive anti tuberculosis treatment for at least 3 months before they can be enrolled);
• Patients who have undergone splenectomy in the past or those who have received splenic radiation therapy within the 12 months prior to their first dose;
• Active infection of hepatitis B virus (HBV) or hepatitis C virus (HCV), except for the following patients: a) HBV infection: patients who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and undergo peripheral blood HBV-DNA testing, with the lower limit of HBV-DNA detection value (i.e. the upper limit of normal value in the laboratory of each research center) can be enrolled; If the baseline HBsAg is positive, continuous antiviral treatment is required after enrollment, and HBV-DNA testing should be conducted every 12 weeks and at EOT visits; b) Patients who are positive for HCV serology but negative for HCV-RNA can be included in the study;
• Patients who are positive for human immunodeficiency virus antibodies (HIV Ab) or anti Treponema pallidum antibodies (TP Ab) (Treponema pallidum antibodies positive);
• Patients with epilepsy or those taking psychotropic or sedative drugs during screening;
• Pregnant or lactating female patients, female/male patients with fertility who refuse to use contraceptive measures during the trial period and within 6 months after the trial ends;
• Patients who have suffered from other malignant tumors within the past 5 years before the first administration (excluding cured carcinoma in situ and basal cell carcinoma of the skin);
• Patients with swallowing difficulties, chronic diarrhea, or oral absorption disorders;

Sponsors & Collaborators

• Chengdu Zenitar Biomedical Technology Co., Ltd: lead

Study Sites (2)

West China Hospital Sichuan University

Chengdu, Sichuan, China

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)

Tianjin, Tianjin Municipality, China

RECRUITING

Study Officials

• Xiao Zhijian

  Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)

  PRINCIPAL INVESTIGATOR

• Niu Ting

  West China Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Wang Fangmei

CONTACT

13808086495; fangmei.wang@zenitar.cn

Sun Liangkun

CONTACT

liangkunsun@zenitar.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 19, 2025
• First Posted: March 2, 2026
• Study Start: March 18, 2026
• Primary Completion (Estimated): December 30, 2027
• Study Completion (Estimated): March 30, 2028
• Last Updated: April 8, 2026

Record last verified: 2026-04

Locations

CN (2)